Hepatitis C

Infectious Disease·MeSH: Liver Cirrhosis

Prevalence

700.0 / 100K

Incidence

15.0 / 100K/yr

11 drugs in development·6 companies·6 clinical trials

Drug Pipeline by Phase

Approved(5)

Drug	Company
ganovo	ARRAY BIOPHARMA INC (ARRY)
mavyret	AbbVie Inc. (ABBV)
MAVYRET / MAVIRET	ENANTA PHARMACEUTICALS INC (ENTA)
MAVYRET® / MAVIRET® (glecaprevir/pibrentasvir)	ENANTA PHARMACEUTICALS INC (ENTA)
promacta	Novartis AG (NVS)

Phase 3(2)

Drug	Company
Bemnifosbuvir-Ruzasvir	Atea Pharmaceuticals, Inc. (AVIR)
Sofosbuvir-Velpatasvir	Atea Pharmaceuticals, Inc. (AVIR)

Phase 2(4)

Drug	Company
bemnifosbuvir	Atea Pharmaceuticals, Inc. (AVIR)
Bemnifosbuvir	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
ruzasvir	Atea Pharmaceuticals, Inc. (AVIR)
Ruzasvir	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

BioSniper tracks 11 drugs in development for Hepatitis C across 6 companies.

There are 6 clinical trials targeting Hepatitis C tracked by BioSniper.

The estimated prevalence of Hepatitis C is approximately 700.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.